These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 14684452)

  • 21. A role for the PKC signaling system in the pathophysiology and treatment of mood disorders: involvement of a functional imbalance?
    Abrial E; Lucas G; Scarna H; Haddjeri N; Lambás-Señas L
    Mol Neurobiol; 2011 Dec; 44(3):407-19. PubMed ID: 21983961
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mood stabilizers target cellular plasticity and resilience cascades: implications for the development of novel therapeutics.
    Bachmann RF; Schloesser RJ; Gould TD; Manji HK
    Mol Neurobiol; 2005 Oct; 32(2):173-202. PubMed ID: 16215281
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lithium's role in neural plasticity and its implications for mood disorders.
    Gray JD; McEwen BS
    Acta Psychiatr Scand; 2013 Nov; 128(5):347-61. PubMed ID: 23617566
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lithium, Stress, and Resilience in Bipolar Disorder: Deciphering this key homeostatic synaptic plasticity regulator.
    Machado-Vieira R
    J Affect Disord; 2018 Jun; 233():92-99. PubMed ID: 29310970
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders.
    Machado-Vieira R; Manji HK; Zarate CA
    Neuroscientist; 2009 Oct; 15(5):525-39. PubMed ID: 19471044
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Mechanism and clinical effects of drugs for mood disorder].
    Nakagawa S; Koyama T
    Ryoikibetsu Shokogun Shirizu; 2003; (38):358-61. PubMed ID: 12877002
    [No Abstract]   [Full Text] [Related]  

  • 27. Emerging experimental therapeutics for bipolar disorder: clues from the molecular pathophysiology.
    Quiroz JA; Singh J; Gould TD; Denicoff KD; Zarate CA; Manji HK
    Mol Psychiatry; 2004 Aug; 9(8):756-76. PubMed ID: 15136795
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pathophysiology of depression: the concept of synaptic plasticity.
    Duman RS
    Eur Psychiatry; 2002 Jul; 17 Suppl 3():306-10. PubMed ID: 15177086
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Multiaxial evaluation of the pathophysiology of mood disorder and therapeutic mechanisms of clinical drugs by neuronal plasticity and neuronal load].
    Omata N; Mizuno T; Mitsuya H; Wada Y
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2013 Nov; 33(5-6):231-6. PubMed ID: 25069263
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The "blue" side of glutamatergic neurotransmission: NMDA receptor antagonists as possible novel therapeutics for major depression.
    Szakacs R; Janka Z; Kalman J
    Neuropsychopharmacol Hung; 2012 Mar; 14(1):29-40. PubMed ID: 22427468
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emerging Novel Treatments for Severe Mood Disorders Involving Cellular Plasticity Cascades.
    Machado-Vieira R; Zarate CA; Manji HK
    Curr Psychos Ther Rep; 2006 Dec; 4(4):181-190. PubMed ID: 25620894
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel drugs and therapeutic targets for severe mood disorders.
    Mathew SJ; Manji HK; Charney DS
    Neuropsychopharmacology; 2008 Aug; 33(9):2080-92. PubMed ID: 18172433
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glutamatergic dysregulation in mood disorders: opportunities for the discovery of novel drug targets.
    Małgorzata P; Paweł K; Iwona ML; Brzostek T; Andrzej P
    Expert Opin Ther Targets; 2020 Dec; 24(12):1187-1209. PubMed ID: 33138678
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glycogen Synthase Kinase-3β as a Putative Therapeutic Target for Bipolar Disorder.
    Dandekar MP; Valvassori SS; Dal-Pont GC; Quevedo J
    Curr Drug Metab; 2018; 19(8):663-673. PubMed ID: 29283064
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of NMDA receptors in the pathophysiology and treatment of mood disorders.
    Ghasemi M; Phillips C; Trillo L; De Miguel Z; Das D; Salehi A
    Neurosci Biobehav Rev; 2014 Nov; 47():336-58. PubMed ID: 25218759
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of neurotrophic factors in the etiology and treatment of mood disorders.
    Duman RS
    Neuromolecular Med; 2004; 5(1):11-25. PubMed ID: 15001809
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antidepressant drugs and cytokines in mood disorders.
    Nishida A; Hisaoka K; Zensho H; Uchitomi Y; Morinobu S; Yamawaki S
    Int Immunopharmacol; 2002 Nov; 2(12):1619-26. PubMed ID: 12469936
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PKC, MAP kinases and the bcl-2 family of proteins as long-term targets for mood stabilizers.
    Manji HK; Chen G
    Mol Psychiatry; 2002; 7 Suppl 1():S46-56. PubMed ID: 11986995
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CNS signal transduction in the pathophysiology and pharmacotherapy of affective disorders and schizophrenia.
    Hudson CJ; Young LT; Li PP; Warsh JJ
    Synapse; 1993 Mar; 13(3):278-93. PubMed ID: 8497811
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A potential role for pro-inflammatory cytokines in regulating synaptic plasticity in major depressive disorder.
    Khairova RA; Machado-Vieira R; Du J; Manji HK
    Int J Neuropsychopharmacol; 2009 May; 12(4):561-78. PubMed ID: 19224657
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.